HC Wainwright & Co. Maintains Buy on Ascendis Pharma, Lowers Price Target to $335
Benzinga Newsdesk 14 hours ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $344 to $335.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $344 to $335.